Medical cannabis provider Tilray Medical has published a scientific study comparing the bioavailability of different cannabinoid formulations.
The pharmacokinetic study looked at two D9-tetrahydrocannabinol: cannabidiol (THC:CBD) formulations.
The oral and oromucosally administered products were given to 12 healthy volunteers under fasting conditions, while blood samples were taken pre-dose and at 16 post-dose time points over 24 hours.
Results revealed that the Cmax for THC and CBD was significantly higher for the Tilray THC:CBD extract compared to nabiximols and neither Tmax nor AUC was significantly different for the two treatments.
Interestingly, the Cmax for nabiximols was significantly higher in males compared to females. Under both treatment conditions, THC and CBD were undetectable 24 hours post-dose, and 11-OH-THC was markedly reduced from its peak.
During the study period, no serious adverse events were reported.
This pilot study shows that oral administration of Tilray THC:CBD extract formulation achieved higher THC and CBD concentrations within a shorter timeframe compared to the oromucosal delivery of nabiximols. These findings may have significant implications for clinical populations using these formulations therapeutically.
"By advancing our understanding of cannabinoid pharmacokinetics, we are better equipped to develop formulations that can significantly enhance therapeutic outcomes," noted José Tempero, Tilray’s Medical Director.
"We extend our heartfelt thanks to our partners in this study for their invaluable contributions and collaboration."
"This pioneering research exemplifies our commitment to advancing the science of medical cannabis. By deepening our understanding of cannabinoid pharmacokinetics, we strive to enhance the therapeutic potential of our products, ultimately improving the quality of life for patients globally," concluded Denise Faltishchek, Chief Strategy Officer and Head of International at Tilray.
